Achieve Life Sciences: FDA Approval Not Assured, But Valuation Justifies Risk
…
Echtzeit-Aktienkurs Achieve Life Sciences Inc.
Bid:
Ask:
Nachrichten zur Achieve Life Sciences Inc. Aktie
Rubedo Life Sciences gibt bekannt, dass der erste Patient mit dem führenden Medikamentenkandidaten RLS-1496 behandelt wurde, dem ersten GPX4-Modulator, der auf pathologische seneszente Zellen abzielt und in die klinische Phase 1 eintritt
SAN FRANCISCO--(BUSINESS WIRE)--Rubedo Life Sciences, Inc. (Rubedo), ein KI-gesteuertes Biotech-Unternehmen im klinischen Stadium, das sich auf die Erforschung und schnelle…
Achieve Life Sciences, Inc. (ACHV) Q1 2025 Earnings Call Transcript
…
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo…
Achieve Life Sciences announces board changes By Investing.com
Achieve Life Sciences announces board changes…
Achieve Life Sciences, Inc. (ACHV) Q2 2024 Earnings Call Transcript
…
Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement
…
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a…
Achieve Life Sciences, Inc. (ACHV) Q1 2024 Earnings Call Transcript
…
Jones Trading sets stock target on Achieve Life Sciences shares By Investing.com
Jones Trading sets stock target on Achieve Life Sciences shares…
Achieve Life Sciences: An Excellent Drug Addressing A Large Market Could Drive 5x Returns
…
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
…
Achieve Life Sciences Q4 2023 Earnings Preview
…
Achieve Life Sciences secures $60 million in funding By Investing.com
Achieve Life Sciences secures $60 million in funding…